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Angiogenesis is known as one of the most important 
and critical steps of bone formation and fracture healing, 
and is driven by a complex interaction of various cyto-
kines. Complications such as delays in bone healing and 
nonunion may therefore be associated with altered con-
centrations of specific angiogenic factors. Pentoxifylline 
(PTX) is a xanthine derivative which has been approved 
for extensive clinical use.[1] It attenuates reperfusion-
associated membrane injury and tissue edema in order 
to suppress leukocyte adhesion and improve hindlimb 
blood flow during the reperfusion period.[2,3]
The aim of this study was to determine the effect of 
PTX through angiogenesis on the healing of critical-
sized segmental defects of the radius diaphysis in a rat 
model, using radiological and histological grading sys-
tems.
Objective: The aim of this study was to determine the effect of pentoxifylline (PTX) on angiogenesis 
and the healing of a critical-sized segmental defect of the radius diaphysis in a rat model, using radio-
logical and histological grading systems.
Methods: The study included 24 female Sprague-Dawley rats (weight: 300±20 g) divided into 4 
groups. A critical-sized segmental defect was created in the radius diaphysis in all rats. In Group 1, 
morcellized iliac crest autografts were used to fill the segmental bone defect. In Group 2, segmental 
bone defects were filled using morcellized iliac crest autografts, and 25 mg/kg/day PTX was applied 
intraperitoneally. In Group 3, the segmental bone defects were not filled, and in Group 4 the segmental 
bone defects were left unfilled, and an intraperitoneal (IP) dose of 25 mg/kg/day PTX was applied. 
Rats were sacrificed at postoperative Week 8, and defects were evaluated using radiographic, histologi-
cal and immunohistochemical methods.
Results: There were significant differences between Group 1 and 2 according to radiological evalua-
tion (p=0.003) and quality of union at the defect site (p=0.01). Union quality was higher in Group 4 
than Group 3 (p=0.01). Cluster of differentiation 31 (CD31) and vascular endothelial growth factor 
(VEGF) levels were higher in Group 2 than in Groups 3 and 4.
Conclusion: According to radiological and histological parameters, PTX appears to improve angio-
genesis and healing of segmental cortical bone defects of the radius in a rat model.
Keywords: Bone graft; bone healing; cortical defect; pentoxifylline.
EXPERIMENTAL STUDY
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materials and methods
The study was carried out at our institution’s Animal 
Research Laboratories, and the experimental protocol 
was approved by the Ethics Committee.
The study included 24 female Sprague-Dawley rats 
weighing approximately 300±20 g. Rats were kept in 
cages in groups of 6 at the same institution. All surgical 
procedures were carried out by the same surgeon under 
ketamine and xylazine anesthesia.
The critical-sized defect model was performed, as 
described by other studies in the literature. The right 
forelimbs of the rats were shaved, prepared, and draped 
in a sterile fashion. A longitudinal incision was made on 
the radius, and the overlying tissues were dissected. The 
middle third of the radius diaphysis was osteotomized, 
and a segmental defect 2 times greater than the radius of 
the bone diaphysis was created (Figure 1).[4,6–8] The de-
fect was irrigated using a saline solution. Postoperative-
ly, the rats were randomly divided into 4 experimental 
groups: morcellized iliac crest autografts were used to fill 
in the segmental bone defects in Group 1; morcellized 
iliac crest autografts were used to fill the segmental bone 
defects, and a dose of 25 mg/kg/day PTX was given in-
traperitoneally in Group 2; segmental bone defects were 
not filled in Group 3; and the segmental bone defects 
were not filled and an intraperitoneal (IP) dose of 25 
mg/kg/day PTX was administered in Group 4 rats. The 
skin was sutured postoperatively using monofilament 
4–0 nylon thread.
Rats were sacrificed using a high dose of ketamine 
and xylazine at postoperative Week 8. The right fore-
limbs were dissected, with care taken to avoid damaging 
the callus tissues. 
Anteroposterior radiographs were taken for each 
specimen (Figures 2a–c). Osseous union was graded ac-
cording to the radiographic evaluation scale prepared by 
Cook et al.[4] No device was used for radiodensity mea-
Fig. 1. Critical-sized bone defect performed at the radius diaphysis. 
[Color figure can be viewed in the online issue, which is avail-
able at www.aott.org.tr]
Fig. 2. (a) Radiographic image of a segmental bone defect filled with morcellized iliac crest autograft. (b) Radiograph-
ic image of a segmental bone defect filled with morcellized iliac crest autograft and receiving IP 25 mg/kg/day PTX. 
(c) Radiographic image of a segmental bone defect which was not filled.
(a) (b) (c)
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surement because previous studies have shown no need 
for any specific device for radiographic evaluation.[4–6,9]
Specimens were placed in a 10% formaldehyde solu-
tion for 24 hours and decalcified in 10% formic acid for 
10 days. 5 μm slides were prepared, and specimens were 
stained using hematoxylin and eosin (HE). Histopatho-
logical evaluation was performed under light microscope. 
Bone healing was determined at the defect site. Histo-
logical evaluation was performed according to the histo-
pathological evaluation scale used by Salkeld et al.[6,9–11]
Immunohistochemical evaluation was performed 
using cluster of differentiation 31 (CD31) and vascular 
endothelial growth factor (VEGF) antibodies (Leica 
Biosystems, Buffalo Grove, IL, USA) to determine 
evidence of angiogenesis. CD31 is a 130 kDa integral 
membrane protein, a member of the immunoglobulin 
super family that mediates cell-to-cell adhesion. It is also 
known as platelet endothelial cell adhesion molecule-1 
(PECAM-1) and has been detected on bone marrow-
derived hematopoietic stem cells and embryonic stem 
cells. CD31-mediated endothelial cell-cell interactions 
are involved in angiogenesis.[12–15] VEGF stimulates the 
mitosis of vascular endothelial cells, induces endothelial 
cell proliferation, promotes cell migration, and inhibits 
apoptosis. In vivo VEGF induces angiogenesis as well 
as permeabilization of blood vessels, and plays a central 
role in the regulation of vasculogenesis. 
In the immunohistochemical evaluation, 3-μm thick 
sections were deparaffinized and mounted on Poly-L-
lysine-coated slides. Sections were placed in a citrate 
buffer (0.01 mol/L; pH: 6), heated in a microwave oven 
for 15 min at maximum power (700 W), and cooled at 
room temperature for 20 min. Tissue sections were in-
cubated with the primary antibodies CD31 and VEGF 
for 1 hr in a humidified chamber at room tempera-
ture. After washing in buffer, the slides were incubated 
with biotinylated goat anti-polyvalent for 15 min and 
in streptavidin peroxidase for an additional 15 min at 
room temperature. The slides were then developed for 
12 min in diaminobenzidine and counterstained with 
hematoxylin. Positive and negative controls were used 
for immunostaining.
The density of microvessels highlighted by CD31 
immunostaining was measured by grid at a magnifica-
tion of x200 using an eyepiece screen with an examina-
tion area of 0.25mm². Results are presented as the num-
ber of microvessels per unit of area. 
VEGF was graded in a semiquantitative manner us-
ing a 1–3+ scale as follows: 1+ indicates that stained 
cells comprise <25% of the representative biopsy; 2+ 
indicates that stained cells comprise 25–50% of the rep-
resentative biopsy; and 3+ indicates that stained cells 
comprise >50% of the representative biopsy.
Statistical evaluation was carried out using Statistical 
Package for the Social Sciences (SPSS) software (SPSS 
Inc., Chicago, IL, USA). Continuous variables are given 
as mean±SD, and categorical variables as numbers and 
percentages. Data were tested for normal distribution 
using the Kolmogorov-Smirnov test. Continuous vari-
ables were compared using the Mann-Whitney U test. 
The Kruskal-Wallis test was used for comparison of the 
categorical variables between groups. All tests of signifi-
cance were two-tailed. A p value <0.05 was considered 
statistically significant.
results
The Kruskal-Wallis test revealed significant radiologi-
cal differences between all groups (p<0.001). Radio-
logical bone union was observed in Groups 1 and 2 only 
(p=0.006), and there was a significant difference be-
tween Groups 1 and 2 (p=0.006). 
 In the histological evaluation, Group 2 had better 
bone union quality than Group 1, while Group 4 had 
better bone union quality than Group 3. There were no 
significant differences between Groups 1 and 2 or be-
tween Groups 3 and 4 according to cortex formation-re-
modeling and graft incorporation-new bone formation.
Immunohistochemical evaluation showed that while 
there were no significant differences between Groups 1 
and 2 in terms of CD31 staining, there were significant 
differences between Groups 1 and 2 in VEGF staining 
(union: p=0.007; cortex: p=0.031; graft: p=0.031). In ad-
dition, there were significant differences between Groups 
2 and 3 and between Groups 2 and 4 for CD31 levels 
(p=0.004, p=0.026, respectively) and VEGF staining 
(union: p=0.03, p=0.002, respectively; cortex: p=0.01, 
p=0.014, respectively; graft: p=0.008, p=0.006, respec-
tively). CD31 staining revealed significant differences be-
tween Groups 3 and 4 (p=0.017), while VEGF grades 
did not. CD31 level was highest in Group 2 (Table 1).
Callus formation and mineralization were observed 
at the bone defect sites in Groups 1 and 2. Significant 
osteoblastic activity was seen in Group 2 (Figure 3).
discussion
In the United States annually, 33 million people are af-
fected by musculoskeletal injuries, and the incidence 
of bone fractures is approximately 6 million.[16,17] As 
bone fractures cause both loss of function and signifi-
cant economic effects related to the subsequent loss of 
productivity, treatment aims to provide sufficient and 
timely fracture healing. Upon fracture, hypoxic-necrotic 
sites develop due to reduced vascularization and oxygen 
pressure, and pH decreases. After this period, cytokines 
are excreted at the fracture site, and the healing period 
begins. Vascularization is important in this early stage 
and is managed by the cytokines which facilitate angio-
genesis. Angiogenesis is assisted by capillary circulation 
from non-injured bone sites. One of the most important 
vascular sites of the bone is the periosteal artery, with 
periosteal circulation playing an important role in early 
fracture healing.[11,16,18,19] Fracture healing is a unique 
type of wound healing response. While the majority of 
fractures heal well, some resist treatment and result in 
Table 1.  Distribution of the radiological, histological, and immunohistochemical evaluations among the groups.
Grade Group 1 Group 2 Group 3 Group 4 p1 p2 p3 p4
  n % n % n % n %
X-ray
 0 0 0 0 0 5 100 6 100
 1 1 16.7 0 0 0 0 0 0
 2 4 66.6 0 0 0 0 0 0 0.006 1.0 <0.001 <0.001
 3 1 16.7 3 50 0 0 0 0
 4 0 0 2 33.3 0 0 0 0
 5 0 0 1 16.7 0 0 0 0
Histounion
 1 3 50 0 0 4 80 0 0
 2 3 50 2 33.3 1 20 6 100 0.011 0.009 0.145 0.003
 3 0 0 4 66.7 0 0 0 0
Histocortex
 0 0 0 0 0 3 60 2 33.3 0.784 0.313 0.008 0.045
 1 3 50 4 66.7 2 40 3 50
 2 3 50 1 16.7 0 0 1 16.7
 3 0 0 1 16.7 0 0 0 0
Histograft
 0 1 16.7 0 0 4 80 2 33.3 0.676 0.106 0.014 0.046
 1 2 33.3 3 50 1 20 2 33.3
 2 0 0 2 33.3 0 0 2 33.3
 3 1 16.7 1 16.7 0 0 0 0
 4 2 33.3 0 0 0 0 0 0
Histounion-
 VEGF 0 0 0 0 1 20 0 0
 0 3 50 0 0 2 40 3 50 0.007 0.545 0.013 0.005
 1 2 33.3 0 0 2 40 3 50
 2 1 16.7 6 100 0 0 0 0
Histocortex-
 VEGF 2 33.3 0 0 2 40 1 16.7
 0 2 33.3 1 16.7 3 60 3 50 0.031 0.190 0.071 0.025
 1 2 33.3 2 33.3 0 0 2 33.3
 2 0 0 3 50 0 0 0 0
Histograft-
 VEGF 2 33.3 0 0 3 60 2 33.3
 0 2 33.3 1 16.7 2 40 4 66.7 0.031 0.399 0.010 0.011
 1 2 33.3 2 33.3 0 0 0 0
 2 0 0 3 50 0 0 0 0
CD31, mean±SD  33.1±11.3 35.0±11.1 11.7±5.7 18.1±7.7 0.310 0.017 <0.001 <0.001
p1: Comparison of Groups 1 and 2; p2: Comparison of Groups 3 and 4; p3: Comparison of Groups 1 and 2 and Groups 3 and 4; p4: Comparison of all groups. 
Histounion: Histological bone union quality; Histocortex: Cortex formation-remodeling; Histograft: Graft incorporation and new bone formation; VEGF: Vascular 
endothelial growth factor; CD31: Cluster of differentiation 31.
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nonunion or malunion. In some cases, the fracture site 
must be supported by bone graft materials.[17,20,21] In 
recent decades, alternative biophysical and biological 
treatment methods have been developed for use in the 
event of impaired fracture healing. Such methods in-
clude stimulation of fracture healing using mechanical, 
electrical, and ultrasound methods; growth promoting 
proteins; and osteogenic, osteoconductive, and osteoin-
ductive methods.[22–24] In the present study, we evaluated 
the adjuvant effect of PTX on the healing of segmental 
bone defects. 
PTX is a xanthine derivative that has been proven to 
attenuate reperfusion-associated membrane injuries and 
tissue edema, as well as suppress leukocyte adhesion and 
improve hindlimb blood flow during the reperfusion pe-
riod.[2,3] It has been shown to improve ischemia/reper-
fusion (I/R) injury by attenuating neutrophil sequestra-
tion, producing reactive oxygen species, and activating 
platelets.[3,25]
In vitro and in vivo studies have demonstrated that 
PTX significantly reduces production of cytokines, in-
cluding tumor necrosis factor alpha (TNF-α). The abil-
ity of the drug to decrease TNF-α level may be related 
to its ability to increase cyclic adenosine monophosphate 
(c-AMP). Due to the discovery of these multiple effects, 
several clinical studies have been conducted. Animal 
studies have documented a beneficial effect of PTX on 
spinal cord ischemia and I/R injury in the liver.[1,24–32] In 
a study using an animal spinal cord ischemia model, Zhu 
et al. concluded that PTX may induce protection against 
ischemia injury in the spinal cord, thereby preventing 
both necrosis and apoptosis.[1] Emrecan et al. showed in 
their in vivo study that iloprost and PTX may reduce I/R 
injury in the early phase of skeletal muscle ischemia.[3]
Delenian et al. evaluated the administration of a com-
bination of PTX and vitamin E with clodronate to reduce 
radiation-induced osteonecrosis and fibrosis, and report-
ed that the combination is useful in the healing of ster-
nocostal and some mandibular osteoradionecrosis. They 
concluded that long-term use of PTX and vitamin E, 
combined with clodronate treatment, is effective, safe, and 
curative for the treatment of refractory osteoradionecro-
sis; furthermore, they found that it induces mucosa and 
bone healing, with significant symptom improvement.[33] 
In the current study, similar results on the effect of PTX 
on the angiogenesis and healing of bone were found.
Some in vitro studies have indicated that elevated lev-
els of c-AMP enhance the bone-forming activity of os-
teoblasts.[34] Kimmel et al.[35] and Shen et al.[36] observed 
that c-AMP and c-AMP-dependent protein kinase may 
promote the growth response of rat bone to intermittent 
pulses of parathyroid hormone (PTH). In addition to the 
rate of synthesis of c-AMP by adenylate cyclase, c-AMP 
levels can be regulated by the rate of hydrolysis to the 
inactive form of 5’ adenosine monophosphate (5’ AMP) 
by cyclic nucleotide phosphodiesterases (PDEs). PDE 
inhibitors are effective in elevating intracellular c-AMP 
levels by inhibiting the breakdown of c-AMP by PDEs. 
Therefore, the administration of PDE-inhibiting com-
pounds such as PTX may have the potential to increase 
bone mass by elevating intracellular c-AMP levels.[37]
Kinoshita et al.[38] reported that the administration 
of PTX increased the density of radiographs of rat fe-
murs and vertebrae in a dose-dependent manner with-
out changing body weight on densitometry analysis. 
Horiuchi et al.[39] injected PTX subcutaneously daily for 
3 weeks from the day of implantation of bone morpho-
genetic protein (BMP)-laden disks and found that os-
sicles from mice treated with 50 mg/kg/day PTX were 
significantly larger in size and had greater calcium con-
tent. However, no differences were noted in mice treated 
with lower doses (5 and 25 mg/kg/day) of PTX. The 
authors did not find any significant differences in bone 
mineral density (BMD) between ossicles in the control 
and PTX treatment groups. The data from the study of 
Horiuchi et al.[39] indicated that PTX has an anabolic ef-
fect on BMP-induced ectopic new bone formation. Sig-
nificant bone formation effect at the osteotomy sites was 
achieved with administration of 25 mg/kg/day PTX in 
the current study.
The exact mechanism by which PTX modulates 
bone formation remains unknown and may be related 
with the pharmacologic effects of the drug. PTX’s 
ability to decrease TNF-α levels may be related to its 
ability to increase c-AMP. TNF-α is a cytokine which 
promotes bone resorption and inhibits bone formation. 
The reduced production of TNF-α in bone marrow as 
a result of PTX may produce an increase in BMD. In 
Fig. 3. Osteoblastic activity, callus formation, and vascularization in a 
rat in Group 2 (HE: x12.5). [Color figure can be viewed in the 
online issue, which is available at www.aott.org.tr]
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addition, PDE inhibitors might improve bone formation 
through the pathway for bone morphogenetic proteins, 
which have the capacity to induce mesenchymal cells to 
differentiate into chondrocytic or osteoblastic lineage.[40] 
The high intracellular c-AMP levels in BMP-responding 
cells amplify the effects of BMP on the cells and stimu-
late the cell differentiation, causing bone formation.[37,41]
Kurtoğlu et al. attempted to determine the adverse 
effects of maternal nicotine exposure during pregnancy 
and lactation, and of the protective effect of PTX on 
neonatal rat bone development. They concluded that 
PTX supplementation prevented the adverse effects 
of maternal nicotine exposure (such as decreased birth 
weight, pregnancy weight gain, bone lengthening, and 
increased apoptosis) on BMD and birth weight.[37]
Aydin et al. evaluated the effect of PTX on closed 
femur shaft fractures after 2- and 3-week periods. While 
they concluded that PTX accelerated healing histologi-
cally in the early phases of fracture healing, the authors 
reported that this effect decreases in the long term. 
Moreover, infection rates in the PTX groups were high. 
The current study was designed with a longer study pe-
riod than that of Aydin et al., and PTX was found histo-
logically and radiologically to accelerate graft incorpora-
tion. There were no infections in any rats, despite our use 
of open surgery and grafting.[42]
In our study, rats that were administered PTX had 
better radiological graft incorporation and histological 
quality of union at the segmental cortical defects. Ad-
ditionally, the non-grafted cortical defects of the rats 
which received PTX showed greater improvement in 
union quality than the control group (Group 3). These 
findings may be the result of the pharmacologic interac-
tion of PTX in cellular response, which causes osteogen-
esis and angiogenesis. Angiogenesis is an important step 
in the healing process of the bone. Groups which were 
exposed to PTX had higher angiogenesis, with high 
CD31 and VEGF levels.
In conclusion, PTX appears to promote bone heal-
ing in segmental bone defects and have the ability to 
improve vascularization and osteogenesis at the defect 
site. Although there are many treatment methods for 
bone healing, the adjuvant effects of agents such as PTX 
should not be overlooked. Further in vivo and in vitro 
studies on these effects are necessary.
Conflics of Interest: No conflicts declared.
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